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ABSTRACT
Aims and background. This paper presents updated estimates of the incidence,
prevalence and mortality of stomach, colorectal, lung, breast, uterine cervix and
prostate cancer and skin melanoma in the Italian population. In particular, point es-
timates for 2012 and time trends from 1970 to 2015 will be provided.
Methods. The presented figures were obtained by summing up the regional epidemi-
ological indicator estimates presented in the other papers of this monographic issue,
which were derived by applying the MIAMOD statistical back-calculation method to
cancer registries survival data and official mortality rates.
Results. Our findings indicate that breast, colon-rectum and prostate will be the can-
cer sites with the highest incidence rates in the forthcoming years. The incidence
rates still tend to increase for breast, male colorectal cancer and female lung cancer
as well as for skin melanoma. By contrast, the incidence of stomach cancer, cervical
cancer and male lung cancer, by far the most common tumor sites up to the early
1990s, will continue to decrease. The mortality estimates showed a decreasing trend
for all considered cancers with the only exception of lung cancer in women.
Conclusion. These results point to the need to reinforce prevention activities by de-
veloping more effective preventive measures for population groups at risk. There is
also a need to support timely and continuous cancer surveillance in the Italian pop-
ulation through cancer registries in order to monitor the spread of the cancer risk and
to evaluate the impact of prevention policies and therapeutic advances.
Introduction
In Italy cancer is the second cause of death after cardiovascular disease, accounting
for about one third of all deaths1. The National Health System, created in 1978 and
mainly funded through taxation, is responsible for providing resident citizens with
health care. The Italian National Health System is organized regionally and the Italian
regions have to prepare periodic cancer control programs. However, the central gov-
ernment issues general policy indications for cancer control and makes available
funds to the regions for their implementation. In order to build an appropriate knowl-
edge-based strategy for cancer control, it is important to have available and continu-
ously monitor quantitative measures of the disease burden, whose major indicators
are incidence, mortality and prevalence. 
Data on cancer mortality have been collected and made available in electronic format
for the entire population by the Italian National Institute of Statistics (ISTAT) since 1970.
Incidence data are collected by cancer registries and distributed by the Italian Network
of Cancer Registries (AIRTUM)2. However, cancer registries data were available for one
third of the national population in 2009, mostly from the north of the country. The cov-
erage of the AIRTUM pool of cancer registries was 48% in the north of Italy, 26% in the
center and 16% in the south3. Coverage increased from 3% in the early 1980s to 15% in
1990 and 25% in 2000, up to the present proportion of 32%. Cancer registries generally
cover province-level areas and most have been active since the late 1980s2. 
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Statistical modeling is a useful complement to the
field collection activity of cancer data. Models can be
applied to empirical datasets with partial coverage de-
riving from cancer registry activity, to estimate epidemi-
ological indicators with national or regional coverage
and to project their estimated values up to the near fu-
ture. In 2007, cancer incidence, mortality and preva-
lence data at the regional and national level were pub-
lished in a monographic issue of Tumori4. The estimates
were projected up to 2010 and were available for the 5
major cancer sites for people aged 0-84 years. The
prevalence proportions have increased markedly, partly
because of the improved survival of cancer patients and
the aging of the population. In 2012, new and updated
national epidemiological estimates and projections are
clearly needed. 
This paper will present updates of the basic epidemio-
logical indicators (incidence, prevalence and mortality)
for the 5 major cancers in Italy as described in the previ-
ous publication (lung, breast, prostate, colon-rectum
and stomach) and will now include skin melanoma and
cancer of the uterine cervix. In particular, point esti-
mates for 2012 and time trends up to 2015 will be pro-
vided. 
Material and methods
The incidence, mortality and prevalence estimates
presented in this paper were obtained by summing up
the absolute number of incident cases, deaths and
prevalent cases, respectively, estimated for the 20 Italian
regions and dividing them by the corresponding popu-
lation data. Regional epidemiological indicator esti-
mates, presented in the other papers of this mono-
graphic issue, were obtained by applying the MIAMOD
statistical back-calculation method to survival and mor-
tality data5-7. For further details we refer to the methods
sections of these papers. 
Briefly, the MIAMOD method was used for the esti-
mation of incidence and prevalence. This statistical
method is based on a back-calculation approach to es-
timate and project the morbidity of chronic irreversible
diseases from mortality and patient survival. The
method relies on the mathematical relationships be-
tween mortality, prevalence, incidence and survival.
The model’s estimation is based on mortality data from
ISTAT for the period 1970-2002, with cause of death
coded according to the ninth revision of the Interna-
tional Classification of Diseases (ICD-9)8. Relative sur-
vival data for the considered cancers for the period of
diagnosis 1985-2002 were obtained from the EURO-
CARE-4 study9. The data refer to the populations cov-
ered by 21 cancer registries in Italy jointly covering
about 25% of the national population.
Table 1 reports the size of the population observed
by the Italian cancer registries in 2009 and the per-
centage of coverage for each region and geographical
area3. 
All incidence, mortality and prevalence estimates were
carried out up to age 99 and for the period 1970-2015. For
all regions, and therefore also in this paper, cervical can-
cer estimates were carried out only up to age 94 years be-
cause the distinction of uterus not otherwise specified
(NOS) deaths into cervix and corpus uteri cancer deaths
in women over 94 years old is not very reliable. Due to
mortality data limitations in the past, only 15-year preva-
lence is reported for cervical cancer. The age-standardized
rates are based on the standard European population.
Results
The number of cases and both the crude and age-
standardized incidence and mortality rates and preva-
lence proportions estimated in Italy for the year 2012
are presented in Tables 2A and 2B, respectively, for men
and women. In this year, colon and rectum was the
most frequent cancer site, with over 54,000 new diag-
noses in both sexes, followed by female breast, prostate
and lung (50,396, 42,604 and 36,555 estimated incident
cases, respectively). The incident cases for the other
cancers were markedly lower, ranging between 13,560
(stomach in both sexes) and 1,515 (cervix) estimated
new cases. The prevalence figures were highest (more
than 10 times the incidence) for breast cancer. Preva-
lence was also high for colorectal and prostate cancer,
but was substantially lower for the other considered
cancer sites as a result of the poor prognosis of these
cancers (lung, stomach) or the low incidence rates
(melanoma, cervix). The highest crude mortality rates
were for lung cancer in men (80 per 100,000 person-
years) and breast cancer in women (35 per 100,000 per-
son-years) and the lowest for melanoma in both sexes
and cancer of the cervix uteri in women. For colorectal,
lung, stomach cancer and melanoma, all the indicators
were higher in men than women, with the exception of
the melanoma prevalence. The highest male:female ra-
tios for incidence and mortality were reported for lung
cancer (3.6 for mortality and 3.2 for incidence), while
the lowest male:female ratios were for melanoma (1.2
and 1.8 for incidence and mortality, respectively). The
time trends of the 3 indicators over the period 1970-
2015 are shown in Figures 1 to 6. They present the age-
standardized incidence in men (Figure 1) and women
(Figure 2), age-standardized mortality in men (Figure 3)
and women (Figure 4), and crude prevalence in men
(Figure 5) and women (Figure 6). The results will be de-
scribed below, grouped by cancer site.
Stomach
The incidence and mortality trends of stomach cancer
were estimated to be clearly decreasing during the
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whole period. Of those analyzed, stomach was the sec-
ond most frequent cancer site in 1970, both in men
(age-adjusted incidence: 51 per 100,000 person-years)
and women (27 per 100,000 person-years). Projections
to 2015 predict stomach cancer incidence as the least
frequent cancer in men (17 per 100,000 person-years)
and the second least frequent in women (9 per 100,000
person-years). The mortality trends were very similar to
the incidence trends: the rates decreased from 44 to 11
per 100,000/year in men and from 22 to 6 per
100,000/year in women in the period 1970-2015. The
prevalence proportions were slowly increasing in both
sexes for the whole period, more in men than in women.
Colon and rectum
The age-standardized incidence rates of colorectal can-
cer were estimated to increase in males during the whole
period up to a projected value of 71 per 100,000 person-
years in 2015, even if the slope tended to flatten in the
most recent years. In women the trend was similar but it
preceded the male trend by several years. The rates in
women were always lower than in men, and were first in-
creasing and then slightly decreasing from 40 to 38 per
100,000/year during the period 2004-2015. The mortality
trends reflected the incidence trends with a more pro-
nounced rate of decrease and with peak rates occurring
about 20 years earlier. The estimated prevalence rose dra-
matically between 1970 and 2015: 10-fold in women and
15-fold in men. 
Lung
The lung cancer age-standardized incidence rates
reached their peak in men during the late 1980s (94 per
100,000/year) and decreased thereafter to an estimated
value of 56 per 100,000 person-years in 2015. In women,
the rates showed a linear increase from 8 per 100,000
person-years in 1970 to 20 per 100,000 person-years in
2015. Due to the very poor prognosis of this cancer, the
mortality trends closely mimic the estimated incidence
trends. In women, lung cancer was estimated to be the
second most frequent cause of cancer death after breast
cancer since 2010. If the present mortality trends will
continue after 2015, lung cancer will become the most
lethal cancer in females. The lung cancer prevalence is
still low in women, due to its low incidence level in the
past. By contrast, the epidemic peak observed in men
during the second half of the 1980s is still reflected in in-
creasing prevalence levels.
Skin melanoma
The melanoma incidence rates were estimated to in-
crease for both genders. In men, we estimated a 13-fold
increase from 1.6 to 21 per 100,000/year during the peri-
od 1970-2015, while in women the increase was lower
(from 2 per 100,000 person-years in 1970 to 17 per
100,000 person-years in 2015). The trends were similar,
with lower values in men until 2001, when the 2 gender-
specific curves crossed over and the male rates increased
more rapidly than the female rates. As a result, the age-
standardized incidence is expected to be about 30% high-
er in men than women in 2015. The mortality rates were
low, due to the generally high survival of melanoma pa-
tients. They reached a peak in both genders during the
1990s and tended to decrease slightly thereafter. By con-
trast, the prevalence is substantial and is rapidly increas-
ing, up to about 270 and 290 per 100,000 in 2015 in men
and women, respectively.
Breast
The age-standardized incidence of female breast can-
cer in Italy was estimated to increase constantly from 43
per 100,000 person-years in 1970 to about 120 per 100,000
person-years in 2015. Trends and projections for breast
cancer incidence from the 1990s onwards are to be taken
with caution because this indicator reflects more the im-
pact of screening activities than the natural evolution of
risk factors. Our projections, based on observations up to
2002, foresee a continuing increase up to 2015, even
though the rise seems to be less pronounced. The mor-
tality rates reached a peak (29 per 100,000/year) by 1987-
89 and then declined steadily to a foreseen level of 17 per
100,000 person-years in 2015. The prevalence was esti-
mated to rise markedly during the reporting period, and
2.5 out of 100 women are expected to live after a diagno-
sis of breast cancer in 2015.
Cervix uteri
The estimated age-standardized incidence and mor-
tality rates for cervical cancer declined markedly during
the period 1980-2015, reaching the lowest figures
among the malignancies considered: 3.5 and 1.3 per
100,000, respectively, in 2015. The prevalence is also ex-
pected to decrease in the future down to an estimated
15-year prevalence of about 50 per 100,000 in 2015.
Prostate
The age-standardized incidence trend of prostate can-
cer was estimated to increase sharply, in particular during
the period 1984-2005, from 31 per 100,000/year to 93 per
100,000/year. From 2005 onwards the rates seemed to sta-
bilize or slightly decline to 89 per 100,000 person-years in
2015. The mortality for prostate cancer slightly increased
from 16 per 100,000 person-years in 1970 to about 19 per
100,000 person-years in 1999 and then started to de-
crease, down to 14 per 100,000 person-years in 2015, with
an estimated reduction of about 25% with respect to the
1999 peak level. Prevalence is estimated to rise consistent-
ly with increasing incidence up to reach a foreseen level of
1.2% of Italian men living in 2015 after a prostate cancer
diagnosis.
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Prevalence
Prevalence increased for all considered cancers except
cervix cancer. The rise was less pronounced in male and
female stomach cancer due to the impressive reduction
of its incidence, while it was striking for breast and
prostate cancer. It is interesting to note the opposite be-
havior of mortality, which decreased for all considered
cancers with the exception of lung cancer in women. 
Discussion
We estimated the burden and trends for 7 major cancers
in the Italian population, together with their time projec-
tions up to 2015. The work provides a 5-year update of
similar data published in 20074. Comparing the previous-
ly published estimates for the same age interval and in-
cluding the common period 2000-2010 can provide useful
insights into the stability of the results of this kind of esti-
mation procedures and on possible uncertainties due to
particular behaviors of specific cancers. Unfortunately, an
exact direct comparison of the rates is not possible be-
cause the 2007 estimates are limited to the ages 0-84 years.
The effect of the different age range will be minimized by
comparing age-standardized rather than crude rates. Fur-
thermore, comparison of the general incidence and
prevalence trends will by and large be indicative of possi-
ble inconsistencies between the 2 sets of estimates.
No relevant differences were found between the 20074
and present estimates for stomach and colorectal cancer in
both men and women. The estimates of the age-standard-
ized incidence rates of stomach cancer were on average 5%
lower for men and 15% lower for women than the present
ones, as can be expected from the exclusion of ages >85
years, but the time trend was similarly decreasing. Also the
age-standardized prevalence estimates were very similar
both for men (old estimate 90 per 100,000 vs 89 per 100,000
according to the new estimate in 2010) and women (46 vs
48). For colorectal cancer we have very similar incidence
figures, with an average annual percent change (APC) of
1% for men. For women, the new all-age incidence esti-
mates including ages >85 years were about 4% higher than
the old ones and the APC was close to zero in both series.
The old and new estimated prevalence was again very sim-
ilar (418 vs 408 per 100,000 for men and 270 vs 266 per
100,000 for women in 2010). The old male lung cancer in-
cidence estimates were about 7% lower than the new ones,
with a similarly decreasing trend (–3% vs –2.5%). For
women, the present incidence estimates are higher than
the old ones (14% more in 2000 and 28% more in 2010) and
have a steeper rate of increase (APC = 0.6 vs 1.7). This indi-
cates that the new data lead to a more pessimistic forecast
of the future epidemic of lung cancer in Italian women. Ac-
cordingly, the new prevalence estimates were consistent
with the old ones for men, but tended to be higher (by
about one third in 2010) for women. The new estimates of
the age-standardized breast cancer incidence rates are
much higher than the old ones: from +11% in 2000 to +22%
in 2010. This discrepancy cannot be due to missing ages
>85 in the 2007 published data but is a real difference in the
results, which also present an increasing incidence trend,
with an APC of 1% per year instead of an almost flat trend
in the old estimates. Even more different are the new esti-
mates for prostate cancer, which can be compared only up
to 2005, the last year provided in the old series. They are
higher than the previous ones, as expected given the very
high proportion of prostate cancers diagnosed at ages 85 or
more, and have a much less steep rate of increase (1.3% vs
3% in the old estimate), mainly due to the effect of the very
recent observations reported by cancer registries and the
different modeling strategy adopted as a result.
Other meaningful comparisons can be made with the
most recently published incidence trends based on the
1998-2005 observational data from the AIRTUM data-
base3. The southern regions are less well represented in
the pool of Italian cancer registries than those of the north
and center of the country. It can be expected that the low-
er representativeness is reflected in the differences be-
tween the AIRTUM data and this paper’s estimates. 
The stomach cancer incidence rates are relatively low
in the southern regions, and this is consistent with our
estimates being 10% lower in both sexes, with similar
decreasing trends. For male colorectal cancer, the age-
standardized incidence rates are close to each other and
also the incidence trends are similar, increasing slightly
during the 2000s. For females, our estimates are very
similar to those of AIRTUM, with stable figures of
around 40 per 100,000. The lung cancer trends are con-
sistently decreasing in men and increasing in women,
with 5% lower values for the Italian estimates with re-
spect to those from the pool of registries. The national
estimates behave similarly to the AIRTUM figures for
melanoma, but are much lower for cervical cancer, par-
ticularly in the most recent years (5.3 vs 6.8 per 100,000
in 2005)3. For prostate cancer the age-standardized inci-
dence rates behave similarly up to the year 2000, after
which our model estimates tend to slow while the AIR-
TUM figures continue to rise, even though at a lesser
pace (92 vs 103 per 100,000 person-years, respectively,
in 2005)3. For breast cancer the incidence trends are
similar, still increasing in the same considered period
(from 96 to 107 per 100,000/year in our estimates and
from 105 to 115 per 100,000/year in the AIRTUM pool
between 1998 and 2005), while an interesting difference
was observed in the incidence rates: our national esti-
mates are lower than the AIRTUM values. This can be
partially due to the greater contribution of the southern
population (with a lower breast cancer incidence) in the
national estimates with respect to the AIRTUM pool of
registries.
The differences between our national estimates and
the AIRTUM estimates10,11 mainly depend on the fact that
our Italian estimations were carried out considering data
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of all Italian regions, even those not covered by cancer
registries, while the AIRTUM estimates were calculated
considering only registry-covered areas. Therefore the
lower concentration of registries in southern Italy reflects
on the final outcome. According to the GLOBOCAN esti-
mates, the Italian incidence rates for breast, prostate, col-
orectal and stomach cancer and skin melanoma are
among the 20 highest in European countries12. In Italy,
low incidence rates were reported for lung and cervix
cancers. According to the CI5C incidence trends up to
2002, the tendency observed for Italy was similar to those
reported for the other European countries13,14.
Projections of the time trends of the main epidemio-
logical indicators are a key feature of the MIAMOD
method. Knowledge of the cancer incidence and mortal-
ity trends is important for gaining a clear epidemiological
picture of the changes that occur in our country in terms
of diagnostic and therapeutic improvements, and there-
fore for defining priorities in health care planning and in
resource allocation for cancer control programs. Further-
more, having at our disposal time trends for the future
can be useful to suggest to policy makers geographical ar-
eas and types of interventions to contrast cancer.
The limitation of the MIAMOD method regards the
projections for those tumors involved in screening pro-
grams, because the MIAMOD estimates are based on
mortality data up to 2002, which only partially reflect
the effect of recent screening activities.
The estimates presented in this paper provide an indi-
cation of the cancer burden in Italy until 2015. Our find-
ings indicate that breast, colon-rectum and prostate will
be the cancer sites with the highest incidence rates in
the forthcoming years. Conversely, the incidence of
lung cancer, which was by far the most common cancer
until the early 1990s, will continue to decrease, although
only in men. The mortality estimates showed a decreas-
ing trend for all studied cancers with the only exception
of lung cancer in women.
These trends will produce a significant effect on the na-
tional hospitalization and care institutions. In a future
perspective, because of the poor opportunities for the
treatment of lung cancer, primary prevention through to-
bacco control is the priority, especially among women.
For the reduction of colorectal cancer and breast cancer
the main goal remains the dissemination of and compli-
ance with organized screening programs. 
These epidemiological findings support the need to in-
tervene on the level of both prevention and health sur-
veillance. On the one hand, it appears necessary to devel-
op more effective preventive measures for population
groups at risk of the damage of smoking (such as women
and young people). On the other, it is necessary to main-
tain a timely and representative surveillance system of
the Italian population through cancer registries to moni-
tor the spread of the cancer burden and evaluate the im-
pact of prevention policies and therapeutic advances.
Table 1 - Population observed by the Italian Network of Cancer Registries by region and geographical area and percentage of re-
gional coverage in 2009
Geographical area Observed population in 2009 (n) Regional coverage in 2009 (%)
Piedmont 1,088,710 25.1
Aosta Valley 0 0.0
Lombardy 3,304,823 35.2
Trentino Alto Adige 974,613 100.0
Veneto 2,294,685 48.8
Friuli Venezia Giulia 1,204,718 100.0
Liguria 875,732 55.0
Emilia Romagna 2,962,001 71.3














South of Italy 3,250,753 15.7
Italy 18,846,847 32.2
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Table 2B - Estimated incidence, mortality and prevalence by cancer site for the year 2012 in Italy. Number of cases and deaths,
crude and European age-standardized (age-std) rates per 100,000 person-years and crude prevalence proportion per 100,000
persons. Age 0-99 years, women.
Incidence Mortality Prevalence
Cancer site Number of Crude Age-std Number of Crude Age-std Number of Crude
cases rate rate deaths rate rate cases proportion
Breast 50,396 174.0 115.1 10,238 35.3 18.5 609,001 2,102.3
Stomach 5,681 19.6 9.3 3,884 13.4 6.1 28,158 97.2
Colon-rectum 23,633 81.6 38.4 8,582 29.6 12.9 168,362 581.2
Lung 10,221 35.3 19.0 7,780 26.9 13.8 25,504 88.1
Melanoma 5,746 19.8 16.0 581 2.0 1.2 72,784 251.4
Cervix 1,515 5.3 4.0 697 2.4 1.5 16,819* 58.9*
*Limited-duration prevalence at 15 years.
Table 2A - Estimated incidence, mortality and prevalence by cancer site for the year 2012 in Italy. Number of cases and deaths,
crude and European age-standardized (age-std) rates per 100,000 person-years and crude prevalence proportion per 100,000
persons. Age 0-99 years, men.
Incidence Mortality Prevalence
Cancer site Number of Crude Age-std Number of Crude Age-std Number of Crude
cases rate rate deaths rate rate cases proportion
Prostate 42,604 145.6 89.7 8,030 27.4 14.7 322,614 1,102.7
Stomach 7,879 28.8 18.2 5,272 19.3 11.8 37,981 138.9
Colon-rectum 31,102 113.8 70.1 11,035 40.4 23.9 191,704 701.2
Lung 26,334 96.2 60.7 21,984 80.3 49.5 63,499 232.0
Melanoma 6,595 24.1 18.7 807 3.0 2.1 59,324 217.0



























Figura 1 - Incidence estimates by cancer site in Italy in the period 1970-2015. Age-standardized rates (European population) per 100,000 person-
years. Age 0-99 years, men.




























































Figura 3 - Mortality estimates by cancer site in Italy in the period 1970-2015. Age-standardized rates (European population) per 100,000 person-
years. Age 0-99 years, men.
Figura 4 - Mortality estimates by cancer site in Italy in the period 1970-2015. Age-standardized rates (European population) per 100,000 person-
years. Age 0-99 years, women.
Figura 2 - Incidence estimates by cancer site in Italy in the period 1970-2015. Age-standardized rates (European population) per 100,000 person-
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Figura 6 - Prevalence estimates by cancer site in Italy in the period 1970-2015. Crude proportion per 100,000 persons. Age 0-99 years, women.
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